List view / Grid view

diffuse large B-cell lymphoma (DLBCL)

EMA releases human medicines highlights 2022 report

17 February 2023 | By Catherine Eckford (European Pharmaceutical Review)

Medicines which represented significant progress in their therapeutic areas have been listed in the European Medicines Agency's Human Medicines Highlights 2022 report.

news

CD19 CAR-T agents to boost blood cancer market

8 February 2023 | By Catherine Eckford (European Pharmaceutical Review)

GlobalData says CD19 CAR-T agents are expected to treat over 13,000 blood cancer patients annually by 2031, driving sales of Breyanzi and Yescarta.

news

First CAR T-cell therapy recommended on NHS

26 January 2023 | By Catherine Eckford (European Pharmaceutical Review)

NICE’s recommendation of Yescarta® means it is the first time patients will be able to access CAR T-cell therapy long-term on the NHS.

article

France’s ATU reform: early access remains possible, but not all diseases are equal

6 December 2022 | By Cécile Matthews (CRA), Charlotte Capdevila

When France's ATU reform was implemented, some viewed it as restrictive. Here, Cécile Matthews and Charlotte Capdevila explore the reform’s impact on early access to oncology drugs and products for rare diseases.

news

FDA priority review for AbbVie lymphoma bispecific antibody

22 November 2022 | By Catherine Eckford (European Pharmaceutical Review)

The FDA has accepted priority review of epcoritamab for adults with relapsed/refractory large B-cell lymphoma, which could be the first subcutaneous bispecific antibody for large B-cell lymphoma.

news

EMA validates AbbVie lymphoma bispecific antibody application

31 October 2022 | By Catherine Eckford (European Pharmaceutical Review)

AbbVie's marketing application for epcoritamab in adults with relapsed/refractory diffuse large B-cell lymphoma has been validated by the European Medicines Agency.

news

EC approves CAR T-Cell therapy for B-cell lymphoma

19 October 2022 | By Izzy Wood (European Pharmaceutical Review)

Yescarta approved by EC for the treatment of large B-Cell lypmphoma and high grade B-cell lymphoma.

drug products of various forms in various types of packaging, including liquid in glass vials and pills/capsules in blister packages - idea of medicines or pharmaceuticals

news

EMA human medicines committee (CHMP) highlights, September 2022

21 September 2022 | By Hannah Balfour (European Pharmaceutical Review)

In its latest meeting, the Committee for Medicinal Products for Human Use (CHMP) recommended 12 medicines for approval, including those for rare diseases, osteoporosis and cancer.

news

CHMP meeting highlights, January 2022

28 January 2022 | By Hannah Balfour (European Pharmaceutical Review)

The EMA’s Human Medicines Committee (CHMP) recommended approval of Paxlovid for COVID-19 and a new gene therapy for large B-cell lymphomas.

Photomicrograph of diffuse B-cell lymphoma

news

Minjuvi^® receives EC approval to treat large B-cell lymphoma

27 August 2021 | By Anna Begley (European Pharmaceutical Review)

European Commission (EC) approves Minjuvi with lenalidomide for the treatment of large B-cell lymphoma in adults.

Business people shaking hands behind technology images

news

Pfizer to acquire Trillium immuno-oncology therapeutics

24 August 2021 | By Anna Begley (European Pharmaceutical Review)

Pfizer will acquire Trillium Therapeutics, an immuno-oncology company, potentially enhancing growth of cancer treatments from 2026.

news

Polivy^® with R-CHP significantly improves lymphoma outcomes

9 August 2021 | By Anna Begley (European Pharmaceutical Review)

Polivy

news

EMA human medicines committee meeting highlights, June 2021

25 June 2021 | By Hannah Balfour (European Pharmaceutical Review)

Drugs recommended for approval by the European Medicines Agency’s human medicines committee included a gene therapy and two generics, among five others.

Red CAR T cells attacking a central larger white 'cancer' cell on a dark turquoise background - idea of CAR T-cell therapy

news

CAR T therapy provides long-lasting remissions in non-hodgkin lymphoma

19 February 2021 | By Hannah Balfour (European Pharmaceutical Review)

Study shows most non-Hodgkin's lymphoma patients who achieve a remission lasting one year remain in remission for five years after receiving Novartis’ Kymriah™.

news

FDA approves third gene therapy for large B-cell lymphoma

8 February 2021 | By Hannah Balfour (European Pharmaceutical Review)

Breyanzi (lisocabtagene maraleucel) was approved on the 54 percent complete remission rate achieved in diffuse large B-cell lymphoma trials.

Cookie	Description
cookielawinfo-checkbox-advertising-targeting	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID	This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged	This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.

Cookie	Description
cf_ob_info	This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob	This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only	This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush	This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db	This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC	This cookie is set by Youtube and is used to track the views of embedded videos.

Cookie	Description
bcookie	This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS	This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang	This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc	This cookie is set by LinkedIn and used for routing.
lissc	This cookie is set by LinkedIn share Buttons and ad tags.
vuid	We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId	This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule	This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session	This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues	This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga	This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat	This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid	This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.

Cookie	Description
advanced_ads_browser_width	This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions	This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info	This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer	This cookie is set by Advanced Ads and sets the referrer URL.
bscookie	This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE	This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr	This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory	This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE	This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.

Recommended

diffuse large B-cell lymphoma (DLBCL)